文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

奈拉滨作为挽救治疗及桥接异基因干细胞移植在118例复发/难治性T细胞急性淋巴细胞白血病/淋巴瘤成人患者中的应用:CAMPUS ALL研究

Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
PubMed 文献 · Am J Hematol · 2020-08-31

这项观察性四期研究纳入27个意大利血液中心2007年5月至2018年11月间118例接受奈拉滨挽救治疗的复发/难治性T-ALL/T-LBL成人患者,总缓解率50%,完全缓解率36%,1年总生存率37%,其中40%患者后续接受异基因造血干细胞移植,移植后2年和5年总生存率分别为46%和38%。

要点

  • 奈拉滨挽救治疗复发/难治性T-ALL/T-LBL成人患者的总缓解率为50%,完全缓解率为36%。
  • 奈拉滨治疗后40%患者接受异基因造血干细胞移植,移植后2年和5年总生存率分别为46%和38%。
  • Ⅲ-Ⅳ级神经毒性发生率为8%,Ⅲ-Ⅳ级血小板减少和中性粒细胞减少发生率分别为41%和43%。

核心结论

  • 在复发/难治性T-ALL/T-LBL成人患者中,奈拉滨是有效选择,总缓解率50%、完全缓解率36%,安全性可接受,仅8%出现Ⅲ-Ⅳ级神经毒性不良事件。
  • 奈拉滨挽救治疗后40%患者可接受异基因造血干细胞移植,移植后2年和5年总生存率分别为46%和38%。

研究设计与样本

  • 观察性四期研究,2007年5月至2018年11月纳入27个意大利血液中心118例接受奈拉滨挽救治疗的复发/难治性T-ALL/T-LBL成人患者。
  • 中位年龄37岁(范围18-74岁),73%为男性,77例诊断为T-ALL,41例为T-LBL,65/118(55%)已接受超过二线治疗。

主要发现

  • 奈拉滨中位周期数为2(范围1-4);43/118(36%)达完全缓解,16例(14%)部分缓解,59例(50%)难治,总缓解率50%。
  • 自奈拉滨首剂起1年总生存概率为37%,中位生存期8个月。
  • 奈拉滨挽救治疗后接受移植的47例(40%)患者1年总生存率显著优于未移植者(58% vs 22%,log-rank P < .001)。
  • 移植后2年和5年总生存概率分别为46%和38%。
  • 75例(64%)发生至少1项药物相关不良事件;Ⅲ-Ⅳ级神经毒性9/118(8%),Ⅲ-Ⅳ级血小板减少和中性粒细胞减少分别报告于41%和43%的病例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The outcome of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL) in adults is poor, with less than 20% of patients surviving at 5 years. Nelarabine is the only drug specifically approved for R/R T-ALL/T-LBL, but the information to support its use is based on limited available data. The aim of this observational phase four study was to provide recent additional data on the efficacy and safety of nelarabine in adults with R/R T-ALL/T-LBL and to evaluate the feasibility and outcome of allogeneic hematopoietic stem cell transplant (SCT) after salvage with nelarabine therapy. The primary endpoints were overall response rate (ORR) and overall survival (OS). Additional endpoints were safety, SCT rate and post-SCT OS. Between May 2007 and November 2018, 118 patients received nelarabine salvage therapy at 27 Italian hematology sites. The median age was 37 years (range 18-74 years), 73% were male, 77 had a diagnosis of T-ALL and 41 of T-LBL, and 65/118 (55%) had received more than two lines of therapy. The median number of nelarabine cycles was two (range 1-4); 43/118 (36%) patients had complete remission (CR), 16 had partial remission (14%) and 59 (50%) were refractory, with an ORR of 50%. The probability of OS, from the first dose of nelarabine, was 37% at 1 year with a median survival of 8 months. The OS at 1 year was significantly better for the 47 patients (40%) who underwent SCT after nelarabine salvage therapy (58% vs 22%, log-rank P < .001). The probability of OS at 2 and 5 years from SCT was 46% and 38%, respectively. Seventy-five patients (64%) experienced one or more drug-related adverse events (AE). Grade III-IV neurologic toxicities were observed in 9/118 (8%) of cases and thrombocytopenia or/and neutropenia (grade III-IV) were reported in 41% and 43% of cases, respectively. In conclusion, this is one of the largest cohorts of adult patients with R/R T-ALL/T-LBL treated in real life with nelarabine. Taking into account the poor prognosis of this patient population, nelarabine represents an effective option with an ORR of 50% and a CR rate of 36%. In addition, 40% of cases following nelarabine salvage therapy could undergo SCT with an expected OS at 2 and 5 years of 46% and 38%, respectively. The safety profile of nelarabine was acceptable with only 8% of cases showing grade III-IV neurological AE.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Candoni A, Lazzarotto D, Ferrara F, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. Am J Hematol. 2020. PMID: 32777149. doi:10.1002/ajh.25957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。